Quality of Life in Depressed Patients in UK Primary Care: The FINDER Study
To investigate the impact of depression and its treatment on health-related quality of life (HRQoL) in a naturalistic, primary care setting in the UK.
The Factors Influencing Depression Endpoints Research (FINDER) study was a European, 6-month, prospective, observational study designed to estimate HRQoL in patients with a clinical diagnosis of depression. This paper examines primary care patients recruited in the UK. HRQoL was measured at baseline and at 3 and 6 months after starting antidepressant therapy using the Short Form 36 Health Status Survey and the European Quality of Life-5 Dimensions (EQ-5D). Regression analysis was used to identify baseline and treatment variables independently and significantly associated with HRQoL. Further analyses included the effect of caseness for depression on HRQoL, the effect of moderate/severe pain at baseline on HRQoL, changes in overall pain, pain interference scores, and the use of different antidepressants by pain cohort.
A total of 608 patients was recruited from 58 centres and mean HRQoL was significantly below reported population norms at baseline. Most improvement in HRQoL was seen at 3 months for EQ-5D, with small additional improvement at 6 months. Worse HRQoL outcomes at 6 months were associated with higher somatic symptoms score, duration of depression at baseline, and switching within antidepressant classes. Patients meeting the criteria for caseness for depression, or with significant pain at baseline showed less improvement in HRQoL scores at 6 months.
Patients presenting with depression in primary care show reduced HRQoL compared to population norms. HRQoL improves during antidepressant treatment particularly within the first 3 months. Nonpainful somatic symptoms, socioeconomic factors, depression variables and switching within antidepressant class predict poor HRQoL outcome. Pain is a common symptom in depressed patients and remains after 6 months’ treatment. Pain and somatic symptoms should be assessed in all patients with depression in primary care.
- WHO. Preamble to the Constitution of the World Health Organization as adopted by the International Health Conference, New York, 19–22 June, 1946; signed on 22 July 1946 by the representatives of 61 states (Official Records of the World Health Organization, no. 2, p. 100) and entered into force on 7 April 1948. http://www.who.int/governance/eb/who_constitution_en.pdf. Accessed 14 Feb 2013.
- Patrick DL, Erickson P. Health status and health policy: quality of life in health care evaluation and resource allocation. New York: Oxford University Press; 1993.
- Hays RD, Wells KB, Sherbourne CD, Rogers W, Spritzer K. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiatry. 1995;52:11–9. CrossRef
- Wells KB, Sherbourne CD. Functioning and utility for current health of patients with depression or chronic medical conditions in managed, primary care practices. Arch Gen Psychiatry. 1999;56:897–904. CrossRef
- Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA. 1989;262:914–9. CrossRef
- Ware JE, Kosinski M, Dewey JE. How to score version 2 of the SF-36® health survey. Lincoln: QualityMetric Incorporated; 2000.
- Brooks R, EuroQol Group. EuroQol: the current state of play. Health Policy. 1996;37:53–72. CrossRef
- Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care. A randomized trial. JAMA. 2001;286:2947–55. CrossRef
- Miller IW, Keitner GI, Schatzberg AF, et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry. 1998;59:608–19. CrossRef
- Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res. 2002;36:383–90. CrossRef
- Dunner DL, Kwong WJ, Houser TL, Richard NE, Donahue RM, Khan ZM. Improved health-related quality of life and reduced productivity loss after treatment with bupropion sustained release: a study in patients with major depression. Prim Care Companion J Clin Psychiatry. 2001;3:10–6. CrossRef
- Walker V, Streiner DL, Novosel S, Rocchi A, Levine MA, Dean DM. Health-related quality of life in patients with major depression who are treated with moclobemide. J Clin Psychopharmacol. 1995;15(4 Suppl. 2):60–7.
- Peveler R, Kendrick T, Buxton M, et al. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Health Technol Assess. 2005;9:1–134.
- Simon GE, VonKorff M, Piccinelli M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression. N Engl J Med. 1999;341:1329–35. CrossRef
- Garcia-Cebrian A, Gandhi P, Demyttenaere K, Peveler R. The association of depression and painful physical symptoms—a review of the European literature. Eur Psychiatry. 2006;21:379–88. CrossRef
- Bair MJ, Robinson RL, Eckert GJ, Stang PE, Croghan TW, Kroenke K. Impact of pain on depression treatment response in primary care. Psychosom Med. 2004;66:17–22. CrossRef
- Garcia-Cebrian A, Bauer M, Montejo AL, et al. Factors influencing depression endpoints research (FINDER): study design and population characteristics. Eur Psychiatry. 2008;23:57–65. CrossRef
- Bauer M, Monz BU, Montejo AL, et al. Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study. Eur Psychiatry. 2008;23:66–73. CrossRef
- Reed C, Monz BU, Perahia DGS, et al. Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER. J Affect Disord. 2009;113:296–302. CrossRef
- Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996;312:1215–8. CrossRef
- Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361–70. CrossRef
- Olsson I, Mykletun A, Dahl AA. The hospital anxiety and depression rating scale: a cross-sectional study of psychometrics and case finding abilities in general practice. BMC Psychiatry. 2005;5:46. CrossRef
- Goldstein DJ, Lu Y, Detke MJ, Hudson J, Iyengar S, Demitrack MA. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics. 2004;45:17–28. CrossRef
- Collins SL, Moore A, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimetres? Pain. 1997;72:95–7. CrossRef
- Ware JE Jr., Kosinski M, Keller SD. SF-36 Physical and mental health summary scales: a user’s manual. Boston: Health Assessment Laboratory, New England Medical Center; 1994:8:21; 8:29.
- Kind P, Hardman G, Macran S. UK Population norms for EQ-5D. York Centre for Health Economics Discussion Paper 172; 1999.
- Daly EJ, Trivedi MH, Wisniewski SR, et al. Health-related quality of life in depression: a STAR*D report. Ann Clin Psychiatry. 2010;22:43–55.
- Munoz RA, McBride ME, Brnabic AJ, et al. Major depressive disorder in Latin America: the relationship between depression severity, painful somatic symptoms and quality of life. J Affect Disord. 2005;86:93–8. CrossRef
- Garcia-Campayo J, Ayuso-Mateos JL, Caballero L, et al. Relationship of somatic symptoms with depression severity, quality of life, and health resources utilization in patients with major depressive disorder seeking health care in Spain. Prim Care Companion J Clin Psychiatry. 2008;10:355–62. CrossRef
- Demyttenaere K, Reed C, Quail D, et al. Presence and predictors of pain in depression: results from the FINDER study. J Aff Disord. 2010 (Epub ahead of print).
- Bair MJ, Robinson RJ, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163:2433–45. CrossRef
- Sapin C, Fantino B, Nowicki ML, Kind P. Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual Life Outcomes. 2004;2:20. CrossRef
- Sobocki P, Ekman M, Ågren H, et al. Health-related quality of life measured with EQ-5D in patients treated for depression in primary care. Value Health. 2007;10:153–60. CrossRef
- Kelly AM. The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain. Emerg Med J. 2001;18:205–7. CrossRef
- National Institute for Health and Clinical Excellence (NICE). Depression: management of depression in primary and secondary care—NICE Guidance: CG23; 2004. http://guidance.nice.org.uk/CG23. Accessed 15 Feb 2013.
- Leuchter AF, Husain MM, Cook IA, et al. Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report. Psychol Med. 2010;40:239–51. CrossRef
- The NHS information centre for health and social care. http://www.dh.gov.uk/en/Healthcare/Primarycare/Primarycarecontracting/QOF/DH_4125653. Accessed 11 Feb 2013.
- Kendrick T, Chatwin J, Dowrick C, et al. Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study. Health Technology Assessment. 2009;13:iii–iv, ix–xi, 1–159.
- Quality of Life in Depressed Patients in UK Primary Care: The FINDER Study
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Neurology and Therapy
Volume 2, Issue 1-2 , pp 25-42
- Cover Date
- Print ISSN
- Online ISSN
- Springer Healthcare
- Additional Links
- Primary care
- Quality of life
- Industry Sectors
- Author Affiliations
- 1. Eli Lilly & Company Ltd., Lilly House, Priestley Road, Basingstoke, Hampshire, RG24 9NL, UK
- 2. Eli Lilly & Company Ltd., Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK
- 3. Health Services and Population Research Department, Section of Primary Care Mental Health, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK
- 4. Clinical Neurosciences Division, Southampton General Hospital, University of Southampton, Southampton, SO16 6YD, UK
- 5. Hiram Consulting Ltd., 11 Cricketers Close, Ackworth, Pontefract, West Yorkshire, WF7 7PW, UK